ArticleMolecular biology reports2026
Exploratory study of DEFB1 genetic variants and human β-defensin-1 expression in monosodium urate crystal-induced arthritis: insights into innate immune regulation.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGout is an inflammatory arthritis triggered by the deposition of monosodium urate crystals and characterized by activation of innate immune pathways. Human β-defensin-1 (hBD-1), encoded by the DEFB1 gene, is an antimicrobial peptide with immunomodulatory functions. However, its role in gout-related inflammation remains unclear. This study aimed to investigate the relationship between DEFB1 variants (rs11362 and rs1800972) and circulating hBD-1 levels in gout.
methodsA total of 81 individuals were enrolled, including 41 with gout and 40 healthy controls. Serum hBD-1 concentrations were quantified by ELISA, and genotyping was performed using TaqMan assays. Genetic associations were evaluated using logistic and linear regression models adjusted for relevant metabolic variables. An ANCOVA was performed to compare hBD-1 levels across genotypes, adjusting for age, serum urate, and triglyceride levels.
resultsSerum hBD-1 levels were significantly lower in individuals with gout compared with controls (median 34.9 vs. 79.3 pg/mL, p < 0.0001). The rs11362 AA genotype was more frequent among controls and was associated with lower odds of gout across multiple inheritance models after adjustment (p < 0.05). In the overall cohort, this genotype was also associated with higher circulating hBD-1 concentrations (p < 0.0001). This association remained significant after adjusting for covariates in ANCOVA (p < 0.001). No significant associations were observed for the rs1800972 variant.
conclusionThese results suggest that variation in the DEFB1 gene may be associated with differences in hBD-1 expression and gout status. The results provide preliminary evidence that supports a possible link between defensin-related innate immune regulation and gout-associated inflammation. However, given the exploratory design and limited sample size, these results should be interpreted as hypothesis-generating rather than confirmatory. Further studies in larger, well-characterized cohorts are needed to confirm these results and clarify their immunological relevance.
Indexed as
Identifiers
42095990What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.